Literature DB >> 24339038

Pregnancy outcomes, embryonic and fetal development in maternal exposure to Chinese medicines.

Chi Chiu Wang1, Lu Li, Clara Bik San Lau, Ping Chung Leung, Kwok Pui Fung.   

Abstract

Chinese medicine is a common name for a collection of Chinese Materia Medica with therapeutic properties for medical treatment and healing. Similar to Western pharmaceuticals, Chinese medicines are not free of risk, and have the potential to cause adverse pregnancy outcomes and affect embryonic and fetal development. However, most clinical data concerning safety of maternal exposure to Chinese medicines during pregnancy are not available and the conclusion remains elusive. Some individual clinical trials of Chinese medicines reported some minor adverse effects during pregnancy, whereas few animal studies identified some adverse maternal and perinatal effects, as well as embryotoxic potentials. Basic research and mechanistic studies of the teratogenicity of Chinese medicines are still lacking. There is an urgent need for testing the safety of Chinese medicines before recommendation and commercialization. Until more reliable and scientific research data become available, clinicians should consider both the risks and benefits before recommending Chinese medicines to pregnant women. More systematic investigations of the safety implications of the use of Chinese medicines are highly recommended, in addition to more clinical trials with a larger sample size to confirm its safety during pregnancy. This review includes a critical overview of available clinical and experimental data and provides directions to study the safety issue of Chinese medicines for pregnancy.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  development; embryotoxicity; herbal medicines; pregnancy

Mesh:

Year:  2013        PMID: 24339038     DOI: 10.1002/bdrc.21050

Source DB:  PubMed          Journal:  Birth Defects Res C Embryo Today        ISSN: 1542-975X


  2 in total

1.  Herbal Medicine (Sihogayonggolmoryeo-Tang or Chai-Hu-Jia-Long-Gu-Mu-Li-Tang) for Treating Hypertension:A Systematic Review and Meta-Analysis.

Authors:  Boram Lee; Chan-Young Kwon
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-09       Impact factor: 2.629

2.  Calls to a teratogen information service regarding potential exposures in pregnancy and breastfeeding.

Authors:  Sarah C Campbell; Tyler T Kast; Manijeh Kamyar; Julia Robertson; Catherine M Sherwin
Journal:  BMC Pharmacol Toxicol       Date:  2016-07-23       Impact factor: 2.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.